P/E ratio for STAAR Surgical (STAA)
P/E ratio as of May 2024 (TTM): 102
According to STAAR Surgical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 102.048. At the end of 2022 the company had a P/E ratio of 59.9.
P/E ratio history for STAAR Surgical from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 59.9 | -65.87% |
| 2021 | 176 | -74.06% |
| 2020 | 677 | 496.72% |
| 2019 | 113 | -64.45% |
| 2018 | 319 | -189.24% |
| 2017 | -358 | 869.18% |
| 2016 | -36.9 | -17.32% |
| 2015 | -44.6 | 12.66% |
| 2014 | -39.6 | -102.45% |
| 2013 | > 1000 | -1227.46% |
| 2012 | -144 | -141.07% |
| 2011 | 350 | -100% |
| 2010 | > 1000 | -1.134325996468E+19% |
| 2009 | -15.5 | 414.5% |
| 2008 | -3.01 | -33.81% |
| 2007 | -4.55 | -60.39% |
| 2006 | -11.5 | -31.63% |
| 2005 | -16.8 | 55.49% |
| 2004 | -10.8 | -56.8% |
| 2003 | -25.0 | 564.55% |
| 2002 | -3.77 | -13.94% |
| 2001 | -4.38 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 26.8 | -73.74% | 🇨🇭 Switzerland |
 Abbott Laboratories ABT | 35.2 | -65.49% | 🇺🇸 USA |
 Cooper Companies COO | 17.0 | -83.34% | 🇺🇸 USA |
 Atrion ATRI | 27.9 | -72.71% | 🇺🇸 USA |
 SurgePays SURG | 4.70 | -95.39% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.